Electromed, Inc. (ELMD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Electromed, Inc. (ELMD) trades at $45.89 with AI Score 94/100 (Grade A+). Electromed, Inc. specializes in developing, manufacturing, and marketing airway clearance therapy products. Market cap: $379.97M, Sector: Healthcare.
Price live · AI analysis from May 6, 2026ELMD stock analysis for 2026: Analysts have set a consensus price target of $38.00 for Electromed, Inc., suggesting 17.2% downside from the current price of $45.89. The AI MoonshotScore is 94/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ELMD: 6/7 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Electromed, Inc. (ELMD) Healthcare & Pipeline Overview
Electromed, Inc. develops and markets airway clearance therapy solutions, notably the SmartVest system utilizing HFCWO technology. Targeting the home healthcare market for patients with respiratory conditions like bronchiectasis and cystic fibrosis, Electromed distinguishes itself through its focus on patient-centric design and connectivity features.
What Is the Investment Thesis for ELMD?
Electromed, Inc. presents a focused investment opportunity within the medical device sector, specifically in airway clearance therapy. The company's consistent profitability, demonstrated by a 13.1% profit margin, and high gross margin of 78.2% indicate efficient operations. Growth is expected to be driven by increasing awareness and adoption of HFCWO therapy for chronic respiratory conditions. Key catalysts include the expansion of the SmartVest Connect platform and potential partnerships to broaden market reach. However, investors may want to evaluate the risks associated with competition and reimbursement pressures within the medical device industry. The company's beta of 0.32 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
ELMD Key Highlights
- Market capitalization of $379.97M reflects Electromed's current valuation in the medical device market.
- P/E ratio of 23.5 indicates investor expectations for future earnings growth relative to its current price.
- Gross margin of 78.2% highlights Electromed's ability to maintain high profitability on its products.
- Profit margin of 13.1% demonstrates effective cost management and operational efficiency.
- Beta of 0.32 suggests the stock is less volatile than the overall market, potentially offering stability to investors.
Who Are ELMD's Competitors?
ELMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HILL Dot Hill Systems Corp. | $9.75 | +0.10% | 46 | |
| VTRS Viatris Inc. | $16.96 | +0.95% | $19.75B | 33 |
| DCTH Delcath Systems, Inc. | $13.48 | +0.00% | $465.35M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +0.00% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.59 | -3.75% | $718.47M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.32M | 68 |
| SENS Senseonics Holdings, Inc. | $5.38 | -4.53% | $224.64M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ELMD's Key Strengths?
- Proprietary HFCWO technology.
- Established brand recognition.
- High gross margin.
- SmartVest Connect platform.
What Are ELMD's Weaknesses?
- Limited product portfolio.
- Reliance on the U.S. market.
- Smaller market capitalization compared to competitors.
- No dividend payout.
What Could Drive ELMD Stock Higher?
- Expansion of SmartVest Connect platform to include additional features and integrations.
- Increasing awareness and adoption of HFCWO therapy for bronchiectasis.
- Strategic partnerships with healthcare providers to expand market reach.
What Are the Key Risks for ELMD?
- Competition from larger medical device companies with greater resources.
- Reimbursement pressures from healthcare payers impacting pricing and profitability.
- Technological advancements by competitors leading to alternative airway clearance therapies.
- Regulatory changes in the medical device industry affecting product approvals and market access.
What Are the Growth Opportunities for ELMD?
- Expansion of SmartVest Connect Platform: Electromed can leverage its SmartVest Connect platform to enhance patient engagement and therapy adherence. By providing personalized therapy management and remote monitoring capabilities, the company can improve patient outcomes and drive adoption of its SmartVest system. The market for connected medical devices is rapidly growing, with a projected market size of $63.5 billion by 2027, offering a significant opportunity for Electromed to expand its reach and market share.
- Strategic Partnerships with Healthcare Providers: Electromed can pursue strategic partnerships with hospitals, clinics, and home healthcare agencies to increase awareness and adoption of its HFCWO therapy. By collaborating with healthcare providers, the company can gain access to a wider patient base and integrate its SmartVest system into standard care protocols. Such partnerships can also facilitate reimbursement and streamline the prescription process, driving revenue growth.
- Geographic Expansion into International Markets: Electromed has the opportunity to expand its presence in international markets, where the prevalence of chronic respiratory diseases is increasing. By targeting specific regions with high unmet needs for airway clearance therapy, the company can diversify its revenue streams and reduce its reliance on the U.S. market. Market research and regulatory approvals will be critical for successful international expansion.
- Development of New Airway Clearance Products: Electromed can invest in research and development to create new and innovative airway clearance products that address unmet needs in the respiratory care market. This could include developing smaller, more portable HFCWO devices or exploring alternative airway clearance technologies. By expanding its product portfolio, the company can attract new customers and strengthen its competitive position.
- Increased Focus on Direct-to-Patient Marketing: Electromed can enhance its direct-to-patient marketing efforts to raise awareness of its SmartVest system and its benefits for individuals with chronic respiratory conditions. By leveraging digital marketing channels, social media, and patient advocacy groups, the company can reach a wider audience and drive demand for its products. This approach can empower patients to take control of their respiratory health and seek out effective airway clearance therapies.
What Opportunities Does ELMD Have?
- Expansion into international markets.
- Strategic partnerships with healthcare providers.
- Development of new airway clearance products.
- Increased direct-to-patient marketing.
What Threats Does ELMD Face?
- Competition from larger medical device companies.
- Reimbursement pressures from healthcare payers.
- Technological advancements by competitors.
- Regulatory changes in the medical device industry.
What Are ELMD's Competitive Advantages?
- Proprietary HFCWO technology in the SmartVest system.
- Established brand reputation in the airway clearance therapy market.
- Strong relationships with physicians and healthcare providers.
- SmartVest Connect platform provides a competitive edge through personalized therapy management.
What Does ELMD Do?
Electromed, Inc., founded in 1992 and headquartered in New Prague, Minnesota, is a medical device company focused on developing, manufacturing, and marketing innovative airway clearance therapies. The company's core product is the SmartVest Airway Clearance System, which utilizes High Frequency Chest Wall Oscillation (HFCWO) technology to help patients mobilize and clear secretions from their lungs. This therapy is particularly beneficial for individuals with chronic respiratory conditions such as bronchiectasis, cystic fibrosis, and neuromuscular diseases. The SmartVest system includes an inflatable therapy garment, an air pulse generator, and a single-hose connection. Electromed has continued to innovate with the SmartVest SQL System and SmartVest Connect, a wireless technology that provides personalized therapy management. In addition to its home healthcare focus, Electromed offers single-patient-use SmartVest and SmartVest Wrap products for acute care settings. The company markets its products directly to patients and through physicians and healthcare providers, both domestically and internationally. Electromed's commitment to improving the quality of life for patients with respiratory conditions has solidified its position in the airway clearance therapy market.
What Products and Services Does ELMD Offer?
- Develops and manufactures the SmartVest Airway Clearance System.
- Offers High Frequency Chest Wall Oscillation (HFCWO) therapy.
- Provides solutions for patients with chronic respiratory conditions.
- Markets products to physicians, healthcare providers, and patients.
- Offers SmartVest Connect, a wireless therapy management portal.
- Provides single-patient-use SmartVest products for acute care.
How Does ELMD Make Money?
- Sells SmartVest Airway Clearance Systems to home healthcare market.
- Generates revenue through direct sales to patients and healthcare providers.
- Offers SmartVest Connect subscription for ongoing therapy management.
- Provides single-use products for acute care settings.
What Industry Does ELMD Operate In?
Electromed operates in the medical device industry, specifically within the airway clearance therapy segment. This market is driven by the increasing prevalence of chronic respiratory diseases such as bronchiectasis and cystic fibrosis. The competitive landscape includes companies offering alternative airway clearance devices and therapies. Electromed differentiates itself through its focus on HFCWO technology and its SmartVest system. The global medical device market is projected to continue growing, driven by technological advancements and an aging population, providing a favorable backdrop for Electromed's growth.
Who Are ELMD's Key Customers?
- Patients with bronchiectasis.
- Patients with cystic fibrosis.
- Patients with neuromuscular disease.
- Hospitals and acute care facilities.
- Home healthcare providers.
Company Profile
Electromed, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New Prague, US. The company is led by CEO James L. Cunniff. ELMD has traded publicly since 2010.
F-Score 7/9Financial Health
Electromed, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 25.68 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 22%Key Financial Metrics
Return on equity for Electromed, Inc. stands at 22.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.0%, showing how much profit it generates from its asset base. ELMD trades at a trailing price-to-earnings ratio of 23.55, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.
ELMD Valuation & Market Position
With a $379.97M market cap, Electromed, Inc. sits in the small-cap segment of the market. Relative to its peer group, ELMD's quantitative score of 94/100 is above the peer average of 59/100.
FY2026 estForward Outlook
Wall Street analysts project Electromed, Inc. revenue of about $73.6M for fiscal 2026, with EPS near $1.22.
ELMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Electromed's future, indicating that those closest to the company believe in its growth potential.
- Community sentiment has shifted positively, with increased discussions highlighting Electromed's innovative respiratory products and their relevance in current healthcare trends.
- Analysts are optimistic about Electromed's expansion into new markets, which could enhance its revenue streams and brand recognition.
- The company has been making strides in improving operational efficiency, which can lead to better profit margins moving forward.
Bear Case
- Concerns about the competitive landscape in the respiratory device market have emerged, as larger players may overshadow Electromed's offerings.
- Some community members express skepticism regarding the sustainability of recent growth, questioning whether it can be maintained long-term.
- Recent supply chain challenges have raised flags about Electromed's ability to meet increasing demand, potentially impacting customer satisfaction.
- Market perception remains cautious, with some investors wary of the volatility in healthcare stocks, especially those reliant on government contracts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ELMD Latest News
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
-
Stocks That Hit 52-Week Highs On Wednesday
· Feb 5, 2020
ELMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ELMD.
Price Targets
Consensus target: $38.00
ELMD MoonshotScore
What does this score mean?
The MoonshotScore rates ELMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Electromed, Inc. Analysis
Leadership: James L. Cunniff
CEO
James L. Cunniff serves as the CEO of Electromed, Inc., bringing extensive experience in the medical device industry to the role. His background includes leadership positions in various healthcare companies, where he focused on strategic planning, product development, and market expansion. Cunniff's expertise spans across multiple therapeutic areas, providing him with a broad understanding of the healthcare landscape. His career is marked by a commitment to innovation and improving patient outcomes through advanced medical technologies.
Track Record: Under James L. Cunniff's leadership, Electromed has focused on expanding its SmartVest product line and enhancing its market presence. Key achievements include the launch of the SmartVest Connect platform and strategic initiatives to increase adoption of HFCWO therapy. Cunniff has also overseen efforts to strengthen relationships with healthcare providers and expand the company's reach in key markets. His leadership has contributed to Electromed's consistent profitability and growth in the airway clearance therapy sector.
ELMD Healthcare Stock FAQ
What does Electromed, Inc. do?
Electromed, Inc. specializes in the development, manufacture, and marketing of airway clearance therapy devices, primarily focusing on High Frequency Chest Wall Oscillation (HFCWO) technology. Their flagship product, the SmartVest system, is designed to help patients with chronic respiratory conditions like bronchiectasis and cystic fibrosis mobilize and clear lung secretions. Electromed markets its products directly to patients and through healthcare providers, offering both home healthcare and acute care solutions. The company's commitment to innovation and patient-centric design has positioned it as a key player in the airway clearance therapy market.
What do analysts say about ELMD stock?
Analyst coverage of Electromed, Inc. (ELMD) typically focuses on its growth potential within the airway clearance therapy market and its financial performance. Key valuation metrics such as P/E ratio and gross margin are closely monitored. Growth considerations include the expansion of the SmartVest Connect platform, strategic partnerships, and international market opportunities. Analyst consensus generally reflects expectations for continued revenue growth and profitability, balanced against the risks associated with competition and reimbursement pressures in the medical device industry. No buy/sell recommendations are made.
What are the main risks for ELMD?
Electromed, Inc. faces several risks inherent to the medical device industry. Competition from larger companies with greater resources poses a significant threat. Reimbursement pressures from healthcare payers could impact pricing and profitability. Technological advancements by competitors may lead to alternative airway clearance therapies. Regulatory changes in the medical device industry could affect product approvals and market access. These factors could impact Electromed's ability to maintain its market position and achieve its growth objectives. Careful monitoring of these risks is essential for investors.
What revenue streams does Electromed, Inc. have in healthcare?
Electromed, Inc.'s primary revenue stream is the sale of its SmartVest Airway Clearance Systems, which utilize High Frequency Chest Wall Oscillation (HFCWO) technology. These systems are sold to both the home healthcare market and acute care settings. Revenue is generated through direct sales to patients, healthcare providers, and hospitals. The company also derives revenue from the SmartVest Connect platform, which offers personalized therapy management and remote monitoring capabilities. Geographically, the majority of Electromed's revenue comes from the United States, with growing opportunities for international expansion.
How does Electromed, Inc. differentiate itself from competitors in the respiratory therapy market?
Electromed, Inc. differentiates itself through its focus on High Frequency Chest Wall Oscillation (HFCWO) technology and its SmartVest system. The SmartVest system is designed for patient comfort and ease of use, promoting adherence to therapy. The SmartVest Connect platform provides personalized therapy management and remote monitoring capabilities, enhancing patient engagement and outcomes. Electromed's commitment to innovation and patient-centric design, combined with its established brand reputation, sets it apart from competitors in the respiratory therapy market. The company's focus on specific respiratory conditions, such as bronchiectasis and cystic fibrosis, also allows for targeted marketing and product development efforts.
What are the key factors to evaluate for ELMD?
Electromed, Inc. (ELMD) holds an AI score of 94/100 (high). P/E: 23.5x vs the S&P 500's ~20-25x. Analysts target $38.00 (-17%). Not financial advice.
How frequently does ELMD data refresh on this page?
ELMD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ELMD's recent stock price performance?
Electromed, Inc. (ELMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary HFCWO technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent reporting period.